drugset / Trial / NCT02581488

Use of Santyl in Diabetic Foot Ulcers

NCT02581488

Phase 4 Completed 102 enrolled Smith & Nephew, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to test the hypothesis that daily treatment of diabetic foot ulcers with an enzymatic debriding agent, SANTYL, for up to 6 weeks will result in more rapid decrease in ulcer area than diabetic foot ulcers treated with a topical treatment containing silver. After meeting study criteria, participants will be randomly assigned to apply SANTYL or a topical treatment containing silver to their to foot ulcer for up to 6 weeks. At the end of 6 weeks, participants will be followed for an additional 4 weeks to examine the outcome of the study treatment.

Timeline

Start
2015-10
Primary completion
2017-01-12
Completion
2017-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic Topical

Indications